Active Ingredient History
Venlafaxine is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor, which is sold under several brand names; one of them is venlafaxine hydrochloride. Venlafaxine hydrochloride is a venlafaxine extended release tablets, which are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD. A major depressive episode (DSM-IV) implies a prominent and relatively persistent depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period. In addition, venlafaxine hydrochloride is indicated for the treatment of social anxiety (SAD), also known as social phobia. Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which others expose to unfamiliar people or to possible scrutiny the person. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The mechanism of the antidepressant action of venlafaxine in humans is believed to be associated with its potentiation of neurotransmitter activity in the CNS. Preclinical studies have shown that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Pain (Phase 4)
Alcohol-Related Disorders (Phase 2/Phase 3)
Alzheimer Disease (Phase 1)
Antidepressive Agents (Phase 4)
Anxiety (Phase 3)
Anxiety Disorders (Phase 4)
Asthma (Phase 4)
Back Pain (Phase 4)
Bariatric Surgery (Phase 1)
Bipolar Disorder (Phase 4)
Body Dysmorphic Disorders (Phase 4)
Bone Diseases (Phase 3)
Brain Injuries, Traumatic (Phase 4)
Breast Neoplasms (Phase 3)
Cancer Pain (Phase 2/Phase 3)
Cholecystectomy, Laparoscopic (Phase 1/Phase 2)
Chronic Pain (Phase 4)
Cocaine-Related Disorders (Phase 2)
Dementia (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 3)
Drug Interactions (Phase 1)
Dysthymic Disorder (Phase 4)
Fibromyalgia (Phase 1/Phase 2)
Fluoxetine (Phase 4)
Gastrectomy (Phase 4)
Gastric Bypass (Phase 4)
Head and Neck Neoplasms (Phase 4)
Healthy Volunteers (Phase 4)
Hot Flashes (Phase 3)
Marijuana Abuse (Phase 2)
Meniere Disease (Phase 2/Phase 3)
Migraine Disorders (Phase 4)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Neck Pain (Phase 2)
Neuralgia (Phase 4)
Obsessive-Compulsive Disorder (Phase 3)
Osteoarthritis (Phase 4)
Pain (Phase 4)
Panic Disorder (Phase 3)
Parkinson Disease (Phase 3)
Pharmacogenetics (Phase 4)
Phobia, Social (Phase 4)
Prostatic Neoplasms (Phase 3)
Psychophysiologic Disorders (Phase 3)
Recurrence (Phase 4)
Schizophrenia (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Spinal Cord Injuries (Phase 4)
Stress Disorders, Post-Traumatic (Phase 4)
Substance Withdrawal Syndrome (Phase 4)
Suicide, Attempted (Phase 2/Phase 3)
Venlafaxine Hydrochloride (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
